Literature DB >> 2680062

Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction.

M R Stratton1, C Fisher, B A Gusterson, C S Cooper.   

Abstract

Previous studies have demonstrated that genes of the ras family (H, K, and N) can be activated by point mutations at codons 12, 13, and 61. In the present study we have used oligonucleotide probes corresponding to these regions to assess the role of ras gene mutations in the genesis of human rhabdomyosarcoma. To increase the sensitivity of this method the appropriate regions of the three ras genes were first amplified using the polymerase chain reaction. The results show that 35% (5/14) embryonal rhabdomyosarcomas investigated contain mutations in the N-ras or K-ras genes. Thus ras gene mutation is implicated in the development of mesenchymal and embryonal tumors in addition to its previously documented role in epithelial and hematological neoplasia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2680062

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.

Authors:  P Rieske; J Bartkowiak; A Szadowska; M Debiec-Rychter
Journal:  Mol Pathol       Date:  1999-04

2.  Atypical protein kinase Cs are the Ras effectors that mediate repression of myogenic satellite cell differentiation.

Authors:  Yuri V Fedorov; Nathan C Jones; Bradley B Olwin
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

3.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

Review 4.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

5.  Zebrafish models of rhabdomyosarcoma.

Authors:  Eleanor Y Chen; David M Langenau
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

6.  Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2.

Authors:  Cristina de Alvaro; Natalia Martinez; Jose M Rojas; Margarita Lorenzo
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

Review 7.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

Review 8.  Zebrafish models of p53 functions.

Authors:  Narie Y Storer; Leonard I Zon
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-05       Impact factor: 10.005

9.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

10.  Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway.

Authors:  Zhizhong Li; Yunyu Zhang; Krishnan Ramanujan; Yan Ma; David G Kirsch; David J Glass
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.